Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL OTCMKTS:FSDDF NASDAQ:MNPR NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$4.85-2.4%$5.99$3.79▼$14.60$272.83M-0.9727,173 shs739,124 shsFSDDFFSD Pharma$13.00-7.5%$20.53$3.43▼$68.66$98.54MN/A11,100 shs221,509 shsMNPRMonopar Therapeutics$42.90-4.5%$38.82$2.40▼$54.30$277.22M1.238,108 shs9,644 shsNMRANeumora Therapeutics$1.63-2.4%$1.62$0.61▼$17.19$270.45M2.91388,338 shs228,327 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-2.55%-15.19%-17.44%-8.97%-22.83%FSDDFFSD Pharma-7.51%-22.85%-55.49%-10.65%+217.07%MNPRMonopar Therapeutics+8.32%+32.42%+29.67%+29.67%+1,726.42%NMRANeumora Therapeutics+0.60%-4.02%+14.38%+81.19%-85.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$4.85-2.4%$5.99$3.79▼$14.60$272.83M-0.9727,173 shs739,124 shsFSDDFFSD Pharma$13.00-7.5%$20.53$3.43▼$68.66$98.54MN/A11,100 shs221,509 shsMNPRMonopar Therapeutics$42.90-4.5%$38.82$2.40▼$54.30$277.22M1.238,108 shs9,644 shsNMRANeumora Therapeutics$1.63-2.4%$1.62$0.61▼$17.19$270.45M2.91388,338 shs228,327 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-2.55%-15.19%-17.44%-8.97%-22.83%FSDDFFSD Pharma-7.51%-22.85%-55.49%-10.65%+217.07%MNPRMonopar Therapeutics+8.32%+32.42%+29.67%+29.67%+1,726.42%NMRANeumora Therapeutics+0.60%-4.02%+14.38%+81.19%-85.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$20.00312.37% UpsideFSDDFFSD Pharma 0.00N/AN/AN/AMNPRMonopar Therapeutics 3.00Buy$71.7567.25% UpsideNMRANeumora Therapeutics 2.22Hold$7.14338.21% UpsideCurrent Analyst Ratings BreakdownLatest FSDDF, CADL, MNPR, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$87.009/3/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $7.009/3/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$77.009/2/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$80.008/27/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$74.008/26/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.008/13/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.007/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.007/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$74.006/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$23.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,218.88N/AN/A$1.41 per share3.44FSDDFFSD Pharma$70K1,407.71N/AN/AN/A∞MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)FSDDFFSD Pharma-$17.52MN/A0.00∞N/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.57N/AN/AN/AN/A-98.95%-87.68%11/11/2025 (Estimated)Latest FSDDF, CADL, MNPR, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38-$0.33+$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/AFSDDFFSD PharmaN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.017.047.04FSDDFFSD PharmaN/A1.811.60MNPRMonopar TherapeuticsN/A33.9333.93NMRANeumora Therapeutics0.1110.5410.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%FSDDFFSD Pharma0.43%MNPRMonopar Therapeutics1.83%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%FSDDFFSD PharmaN/AMNPRMonopar Therapeutics20.50%NMRANeumora Therapeutics26.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableFSDDFFSD Pharma107.58 millionN/ANot OptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableNMRANeumora Therapeutics108161.95 million118.54 millionOptionableFSDDF, CADL, MNPR, and NMRA HeadlinesRecent News About These CompaniesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 26.3% in AugustSeptember 10 at 6:40 PM | marketbeat.comNuveen LLC Takes $221,000 Position in Neumora Therapeutics, Inc. $NMRASeptember 8 at 3:04 AM | marketbeat.comGraham Capital Management L.P. Has $1.16 Million Holdings in Neumora Therapeutics, Inc. $NMRASeptember 6, 2025 | marketbeat.comNeumora Therapeutics to Participate in Upcoming Conferences in SeptemberSeptember 2, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Sells 2,899,770 Shares of Neumora Therapeutics, Inc. $NMRAAugust 27, 2025 | marketbeat.comNeumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861August 20, 2025 | msn.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by AnalystsAugust 16, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by XTX Topco LtdAugust 14, 2025 | marketbeat.comFederated Hermes Inc. Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)August 11, 2025 | marketbeat.comQ3 EPS Estimate for Neumora Therapeutics Boosted by AnalystAugust 11, 2025 | marketbeat.comWilliam Blair Issues Positive Outlook for NMRA EarningsAugust 11, 2025 | marketbeat.comNeumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215August 7, 2025 | tipranks.comNeumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215August 7, 2025 | msn.comNeumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comNeumora Therapeutics Reports Q2 2025 Financial ResultsAugust 7, 2025 | tipranks.comNeumora Therapeutics reports Q2 EPS (33c), consensus (37c)August 6, 2025 | msn.comNeumora (NMRA) Q2 Loss Improves 10%August 6, 2025 | aol.comANeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comMizuho Raises Price Target for Neumora (NMRA), Keeps Outperform RatingJuly 30, 2025 | msn.com5 Alzheimer’s Readouts To WatchJuly 28, 2025 | biospace.comBNeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFSDDF, CADL, MNPR, and NMRA Company DescriptionsCandel Therapeutics NASDAQ:CADL$4.85 -0.12 (-2.41%) Closing price 04:00 PM EasternExtended Trading$4.85 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.FSD Pharma OTCMKTS:FSDDF$13.00 -1.06 (-7.51%) As of 09/8/2025FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.Monopar Therapeutics NASDAQ:MNPR$42.90 -2.03 (-4.52%) Closing price 04:00 PM EasternExtended Trading$42.93 +0.03 (+0.07%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Neumora Therapeutics NASDAQ:NMRA$1.63 -0.04 (-2.40%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.31%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
